Kenta J. Yoshida

Harnessing Quantitative Medicine to Advance Oncology Drug Development

Oncology drug development continues to have a high attrition rate despite major advances in therapeutic modalities such as antibody-drug conjugates, bispecific antibodies, cell therapies, and cancer vaccines. Critical development decisions are often made under substantial uncerta...